Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1556430 | 1.00 | CCKBR (0.54) | CCKBRCCKAR | |
| SCHEMBL6177344 | 1.00 | CCKBR (0.54) | CCKBRCCKAR | |
| SCHEMBL1556431 | 1.00 | CCKBR (0.54) | CCKBRCCKAR | |
| SCHEMBL19949394 | 1.00 | CCKBR (0.54) | CCKBRCCKAR | |
| SCHEMBL6177296 | 1.00 | CCKBR (0.54) | CCKBRCCKAR | |
| Water SCHEMBL1394819 | 0.99 | CCKBR (0.53) | CCKBRCCKAR | |
| Water SCHEMBL29806115 | 0.99 | CCKBR (0.53) | CCKBRCCKAR | |
| Water SCHEMBL1394812 | 0.99 | CCKBR (0.53) | CCKBRCCKAR | |
| SCHEMBL6177951 | 0.99 | CCKBR (0.53) | CCKBRCCKAR | |
| SCHEMBL6177958 | 0.99 | CCKBR (0.53) | CCKBRCCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122056884-A | Methods of treating pancreatic cancer | 坎莫森特里克斯公司 | 2026-05-19 | — | — | CN | claimed |
| US-20250213523-A1 | COMBINATION OF HDAC INHIBITORS AND STATINS FOR USE IN THE TREATMENT OF PANCREATIC CANCER | ISTITUTO NAZIONALE TUMORI IRCCS - FONDAZIONE G. PASCALE (IT) | 2025-07-03 | — | — | US | claimed |
| EP-4504165-A1 | COMBINATION OF HDAC INHIBITORS AND STATINS FOR USE IN THE TREATMENT OF PANCREATIC CANCER | Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale (IT) | 2025-02-12 | — | — | EP | claimed |
| US-11890276-B2 | Methods of treating pancreatic cancer | CHEMOCENTRYX, INC. (US) | 2024-02-06 | — | — | US | claimed |
| WO-2023194441-A1 | COMBINATION OF HDAC INHIBITORS AND STATINS FOR USE IN THE TREATMENT OF PANCREATIC CANCER | ISTITUTO NAZIONALE TUMORI IRCCS - FONDAZIONE G. PASCALE (IT) | 2023-10-12 | — | — | WO | claimed |
| CN-122094689-A | Combination therapy of diacylglycerol kinase (DGK) alpha inhibitors with other therapies | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122056884-A | Methods of treating pancreatic cancer | 坎莫森特里克斯公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4739310-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-05-13 | — | — | EP | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4619411-A1 | DUAL RECEPTOR TARGETING RADIOLIGANDS AND USES THEREOF | Full-Life Technologies HK Limited (HK) | 2025-09-24 | — | — | EP | disclosed |
| US-20250213523-A1 | COMBINATION OF HDAC INHIBITORS AND STATINS FOR USE IN THE TREATMENT OF PANCREATIC CANCER | ISTITUTO NAZIONALE TUMORI IRCCS - FONDAZIONE G. PASCALE (IT) | 2025-07-03 | — | — | US | disclosed |
| CN-120129690-A | Dual receptor targeted radioligands and uses thereof | 辐联科技香港有限公司 | 2025-06-10 | — | — | CN | disclosed |
| WO-2024083224-A1 | DUAL RECEPTOR TARGETING RADIOLIGANDS AND USES THEREOF RELATED APPLICATIONS | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-04-25 | — | — | WO | disclosed |
| US-11945805-B2 | Inhibitors of CXCR2 | CHEMOCENTRYX, INC (US) | 2024-04-02 | — | — | US | disclosed |
| EP-3383386-B1 | MODULATORS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX INC (US) | 2024-02-14 | — | — | EP | disclosed |
| US-11890276-B2 | Methods of treating pancreatic cancer | CHEMOCENTRYX, INC. (US) | 2024-02-06 | — | — | US | disclosed |
| US-11820759-B2 | Modulators of chemokine receptors | CHEMOCENTRYX, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2023194441-A1 | COMBINATION OF HDAC INHIBITORS AND STATINS FOR USE IN THE TREATMENT OF PANCREATIC CANCER | ISTITUTO NAZIONALE TUMORI IRCCS - FONDAZIONE G. PASCALE (IT) | 2023-10-12 | — | — | WO | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| US-20220153733-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820759-B2 | Modulators of chemokine receptors | CCR5, CXCR3, CCR2 | CCKBR 212/4885CCKAR 137/4885 |
| US-11890276-B2 | Methods of treating pancreatic cancer | RNASE1, KRAS, PNLIP | CCKBR 842/4885CCKAR 1250/4885 |
| US-11945805-B2 | Inhibitors of CXCR2 | CXCR2, CXCR3, CXCR1 | CCKBR 206/4885CCKAR 162/4885 |
| US-20220153733-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CCR2, CCR1, CCR5 | CCKBR 384/4885CCKAR 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.